TFRC and systemic inflammatory response syndrome: Some clinical studies suggest the use of omega interferon7, a soluble transferrin receptor (CPV-2 receptor)8, antiviral drugs9,10, and hyperimmune serum11 as treatments aimed at reducing the viral load instead of solving the sepsis and the systemic inflammatory response syndrome (SIRS), critical elements linked to the high mortality rate of CPE4.